articleThe Lancet OncologyJan 8, 2013Closed access

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

GGGwénaëlle GravisKFKarim FizaziFJFlorence JolySOStéphane OudardFPFranck Priou

Institut Paoli-Calmettes · Institut Gustave Roussy · +30 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

737
total citations
FWCI
41.39
Percentile
100%
References
28
Citations per year

Authors

33

Topics & keywords

Topics
Keywords
  • Medicine
  • Docetaxel
  • Androgen deprivation therapy
  • Prostate cancer
  • Internal medicine
  • Oncology
  • Estramustine
  • Clinical endpoint
No related works found for this paper.

Funding